Treatment advances in posttransplant lymphoproliferative disease

Current Opinion in Hematology

Volumn 17, Issue 4, 2010, Pages 368-374

  Dinardo, Courtney D ^a   Tsai, Donald E ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

arginine butyrate; cytotoxic T lymphocytes; Epstein Barr virus; posttransplant lymphoproliferative disease

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; ARGININE BUTYRATE; CYCLOPHOSPHAMIDE; GANCICLOVIR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PREDNISONE; RAPAMYCIN; RITUXIMAB; UNCLASSIFIED DRUG; VALACICLOVIR; VIRUS VECTOR; ARGININE; BUTYRIC ACID DERIVATIVE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

CELL THERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG INHIBITION; EPSTEIN BARR VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; ADOPTIVE TRANSFER; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG EFFECTS; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISORDERS; PROCEDURES; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANTIBODIES, MONOCLONAL; ARGININE; BUTYRATES; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOPROLIFERATIVE DISORDERS; T-LYMPHOCYTES, CYTOTOXIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED;

EID: 77954085940     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328339018c     Document Type: Review

References (47)

1. Harris NL, Frizzera G, Knowles DM. Posttransplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 264-269.
2. Swerdlow SH, Webber SA, Chadburn A, Ferry J. Post transplant lympho-proliferative disorders. In: Swerdlow SH, Campo E, Harris NL, editors. Classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp. 342-349.
3. Dotti G, Fiocchi R, Mota T, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 2002; 74:1095-1102.
4. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttrans-plant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68:1517-1525.
5. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4:222-230.
6. Penn I. Posttransplant malignancy: the role of immunosuppresion. Drug Saf 2000; 23:101-113.
7. Green M. Management of Epstein-Barr virus-induced posttransplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1:103-108.
8. Shapiro R, Nalesnik MA, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999; 68:1851-1854.
9. Norman DJ, Turka LA. Primer on transplantation. 2nd ed. Mt. Laurel, New Jersey: American Society of Transplantation; 2001:; 311-3118.
10. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113:4992-5001.
11. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71:1076-1088.
12. Frey NV, Tsai DE. The management of posttransplant lymphoproliferative disorder. Med Oncology 2007; 24:125-136.
13. Knight JS, Tsodikov A, Cibrik DM, et al. Lymphoma after solid organ trans-plantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009; 27:3354-3362.
14. Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplant lymphoproliferative disorder. Transplantation 2008; 86:215-222.
15. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6:569-576.
16. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107:3053-3057.
17. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11:113-116.
18. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD20 antibody rituximab in patients with posttransplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5:2901-2906.
19. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in posttransplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115:112-118.
20. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99:4364-4369.
21. Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007; 7:1648-1655.
22. Styczynski J, Einsele H, Gil L, et al. Outcome of treatment of Epstein-Barr virus-related posttransplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11:383-392.
23. Swinnen LJ. Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation. Leuk Lymphoma 1997; 28:89-101.
24. Mamzer-Bruneel MF, Lome C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late postkidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000; 18:3622-3632.
25. Buell JF, Gross TG, Hanaway MJ, et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005; 37:956-957.
26. Gross TG, BucuvalasJ, Park J, etal. Low dose chemotherapy for the treatment of refractory posttransplant lymphoproliferative disease in children. J Clin Oncol 2005; 23:6481-6488.
27. Trappe R, Hinrichs C, Appel U, et al. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immuno suppression. Am J Transplant 2009; 9:2331-2337.
28. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5:671-688.
29. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16:525-537.
30. Jimenez-River C, Avitzur Y, Fecteau AH, et al. Sirolimus for pediatric liver transplant recipients with posttransplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 2004; 8:243-248.
31. Cullis B, D'Souza R, McCullagh P, etal. Sirolimus-induced remission of post transplantation lymphoproliferative disorder. Am J Kidney Dis 2006; 47:E67-E72.
32. Garcia VD, Bonamigo Filho JL, Neumann J, et al. Rituximab in association with rapamycin for posttransplant lymphoproliferative disease treatment. Transpl Int 2003; 16:202-206.
33. MathewT, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18:446-449.
34. Kirk AD, Cherikh WS, Ring M. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7:2619-2625.
35. Humar A, Hebert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006; 81:856-861.
36. Funch DP, Brady J, Ko HH, et al. Methods and objectives of a large US multicenter case control study of posttransplant lymphoproliferative disorder in renal transplant patients. Recent Results Cancer Res 2002; 159:81-88.
37. Faller DV, Mentzer SJ, Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 2001; 13:360-367.
38. Perrine SP, Hermine O, Small T, et al. A phase I/II trial of arginine butyrate and ganciclovir in patients with Epstein-Barr-virus-associated lymphoid malignancies. Blood 2007; 109:2571-2578.
39. Kanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Ann Rev Microbiol 2000; 54:19-48.
40. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplant. N Engl J Med 1994; 330:1185-1191.
41. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91:3654-3661.
42. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allo-geneic transplant recipients. Blood 1998; 92:1549-1555.
43. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999; 96:10392-10396.
44. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108:2942-2949.
45. Wilkie G, Taylor C, Jones M, et al. Establishment and characterization of a bank of CTL for immunotherapy of EBV-associated diseases. J Immunother 2004; 27:309-316.
46. Haque T, Wilkie W, Taylor C, et al. Treatment of EBV-positive post transplant lymphoproliferative disease (PTLD) using partially HLA-matches allogeneic cytotoxic T cells. Lancet 2002; 360:436-442.
47. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110:1123-1131.